Physicians balk at price of Pfizer’s heart drug that they helped to develop

(By Maia Anderson for Becker’s Hospital Review)

Some of the physicians who helped Pfizer develop its recently-approved blockbuster heart disease drug, tafamidis, are now speaking out against the drug’s $225,000 a year price tag, according to Bloomberg.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.